Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barrier Therapeutics To Submit Amended J&J Miconazole Diaper Rash NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Barrier plans to submit the application by year-end, seeking a narrower indication than the original Johnson & Johnson NDA. Barrier's Phase III study of Zimycan in Candida-associated diaper dermatitis was designed to address FDA concerns over the scope and definition of the non-specific diaper dermatitis indication J&J had pursued for the ointment, then called Pediastat.

You may also be interested in...

Swift Pace Of Accelerated Approval Submissions Suggests Strong Constituency For US FDA Program

FDA may be evaluating the future of accelerated approval, but data from the Pink Sheet’s Performance Tracker shows growth in the submissions and approvals over the past five years.

Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Pink Sheet Podcast: New Drug Submissions Lag, More US FDA Emergency Use Authorizations On The Way, BsUFA Revenue Misses Estimates

Pink Sheet reporter and editors discuss the lower application submission rate, another EUA for a potential coronavirus treatment, and the biosimilar user fee program missing revenue estimates again.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts